These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28950729)

  • 1. Self-delivering prodrug-nanoassemblies fabricated by disulfide bond bridged oleate prodrug of docetaxel for breast cancer therapy.
    Zhang S; Guan J; Sun M; Zhang D; Zhang H; Sun B; Guo W; Lin B; Wang Y; He Z; Luo C; Sun J
    Drug Deliv; 2017 Nov; 24(1):1460-1469. PubMed ID: 28950729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo tailor-made protein corona of a prodrug-based nanoassembly fabricated by redox dual-sensitive paclitaxel prodrug for the superselective treatment of breast cancer.
    Zhang D; Yang J; Guan J; Yang B; Zhang S; Sun M; Yang R; Zhang T; Zhang R; Kan Q; Zhang H; He Z; Shang L; Sun J
    Biomater Sci; 2018 Aug; 6(9):2360-2374. PubMed ID: 30019051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational Engineering Docetaxel Prodrug Nanoassemblies: Response Modules Guiding Efficacy Enhancement and Toxicity Reduction.
    Wang D; Li L; Xu H; Sun Y; Li W; Liu T; Li Y; Shi X; He Z; Zhai Y; Sun B; Sun J
    Nano Lett; 2023 Apr; 23(8):3549-3557. PubMed ID: 37053460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the Superiority of Diselenium Bond on Docetaxel Dimeric Prodrug Nanoassemblies: Small Roles Taking Big Responsibilities.
    Zuo S; Sun B; Yang Y; Zhou S; Zhang Y; Guo M; Sun M; Luo C; He Z; Sun J
    Small; 2020 Nov; 16(45):e2005039. PubMed ID: 33078579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulating a single thioether-bridged oleate prodrug into a self-nanoemulsifying drug delivery system to facilitate oral absorption of docetaxel.
    Cui W; Zhang S; Zhao H; Luo C; Sun B; Li Z; Sun M; Ye Q; Sun J; He Z
    Biomater Sci; 2019 Feb; 7(3):1117-1131. PubMed ID: 30638237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing the Role of Connecting Bonds and Modifying Chains in the Rational Design of Prodrug Nanoassemblies.
    Wang D; Du C; Wang S; Li L; Liu T; Song J; He Z; Zhai Y; Sun B; Sun J
    ACS Appl Mater Interfaces; 2022 Nov; 14(45):51200-51211. PubMed ID: 36397309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model.
    Taghipour YD; Zarebkohan A; Salehi R; Talebi M; Rahbarghazi R; Khordadmehr M; Khavandkari S; Badparvar F; Torchilin VP
    Sci Rep; 2024 Oct; 14(1):24603. PubMed ID: 39427007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minor Changes in Response Modules Leading to a "U-Shaped" Conversion Rate of Docetaxel Prodrug Nanoassemblies.
    Li W; Wang D; Zhao H; Xu H; Li L; Huang Y; Shi X; Sun J; He Z; Sun B
    Nano Lett; 2024 Jan; 24(1):394-401. PubMed ID: 38147432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox-responsive nanoparticles based on Chondroitin Sulfate and Docetaxel prodrug for tumor targeted delivery of Docetaxel.
    Li Y; Chen X; Ji J; Li L; Zhai G
    Carbohydr Polym; 2021 Mar; 255():117393. PubMed ID: 33436222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two kinds of docetaxel-vitamin E prodrugs: In vitro evaluation and in vivo antitumor activity.
    Wang J; Xue P; Zhou J; Li L; Xu L; Wang Y
    Int J Pharm; 2016 May; 505(1-2):352-60. PubMed ID: 27085643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photosensitizer-driven nanoassemblies of homodimeric prodrug for self-enhancing activation and synergistic chemo-photodynamic therapy.
    Zhang S; Wang Z; Kong Z; Wang Y; Zhang X; Sun B; Zhang H; Kan Q; He Z; Luo C; Sun J
    Theranostics; 2021; 11(12):6019-6032. PubMed ID: 33897896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of lipid emulsions of docetaxel-linoleic acid conjugate in breast cancer.
    Zhang T; Li M; Yang R; Zhang D; Guan J; Yu J; Yang B; Zhang H; Zhang S; Liu D; Wang Y
    Int J Pharm; 2018 Jul; 546(1-2):61-69. PubMed ID: 29763687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the optimal chain length of modification module in disulfide bond bridged paclitaxel prodrug nanoassemblies for breast tumor treatment.
    Wang D; Huang Y; Yuan J; Wang S; Sheng J; Zhao Y; Zhang H; Wang X; Yu Y; Shi X; He Z; Liu T; Sun B; Sun J
    J Control Release; 2024 Nov; 375():47-59. PubMed ID: 39222794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small changes in the length of diselenide bond-containing linkages exert great influences on the antitumor activity of docetaxel homodimeric prodrug nanoassemblies.
    Li L; Zuo S; Dong F; Liu T; Gao Y; Yang Y; Wang X; Sun J; Sun B; He Z
    Asian J Pharm Sci; 2021 May; 16(3):337-349. PubMed ID: 34276822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel prodrug self-assembled nanosystem: Synthesis, formulation and cytotoxicity.
    Jing F; Guo Q; Xu W; Qu H; Sui Z
    Bioorg Med Chem Lett; 2018 Feb; 28(4):826-830. PubMed ID: 29395972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction-Responsive Docetaxel Prodrug Encapsulated within Human Serum Albumin Nanoparticles for Cancer Therapy.
    Zhang Y; Zhang H; Wang J; Liu C; Xing H; Jiang Y; Li X
    Mol Pharm; 2023 May; 20(5):2513-2526. PubMed ID: 37071030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redox-sensitive prodrug nanoassemblies based on linoleic acid-modified docetaxel to resist breast cancers.
    Li M; Zhao L; Zhang T; Shu Y; He Z; Ma Y; Liu D; Wang Y
    Acta Pharm Sin B; 2019 Mar; 9(2):421-432. PubMed ID: 30972286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox-responsive polymeric micelles formed by conjugating gambogic acid with bioreducible poly(amido amine)s for the co-delivery of docetaxel and MMP-9 shRNA.
    Kang Y; Lu L; Lan J; Ding Y; Yang J; Zhang Y; Zhao Y; Zhang T; Ho RJY
    Acta Biomater; 2018 Mar; 68():137-153. PubMed ID: 29288085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precisely albumin-hitchhiking tumor cell-activated reduction/oxidation-responsive docetaxel prodrugs for the hyperselective treatment of breast cancer.
    Wei W; Luo C; Yang J; Sun B; Zhao D; Liu Y; Wang Y; Yang W; Kan Q; Sun J; He Z
    J Control Release; 2018 Sep; 285():187-199. PubMed ID: 30017721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the Promising Potential of High Permeation Vesicle-Mediated Localized Transdermal Delivery of Docetaxel in Breast Cancer To Overcome the Limitations of Systemic Chemotherapy.
    Bathara M; Date T; Chaudhari D; Ghadi R; Kuche K; Jain S
    Mol Pharm; 2020 Jul; 17(7):2473-2486. PubMed ID: 32496783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.